# Axatilimab and olaparib in BRCA/PALB2-associated metastatic breast cancer

Source: https://onco.cc/trials/nct06488378/  
OnCo record `nct06488378` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This early study combines a DNA-repair drug with a treatment targeting macrophages in advanced breast cancer. It is recruiting, with strict lung-history requirements.

## Summary

Registry status recruiting, last updated 2026-09-02. Enrollment is 20 estimated. Metastatic or unresectable HER2-negative breast cancer with a deleterious or suspected deleterious germline/somatic BRCA1/2 mutation or germline PALB2 mutation, documented by a CLIA-certified laboratory. Axatilimab targets CSF1R and is combined with olaparib in phase 1b. The registry excludes a history of pneumonitis or ILD, or baseline evidence of either. Dana-Farber and Mayo are listed recruiting; cohort/site slots need confirmation. This human two-drug study is distinct from preclinical three-drug PARP/CSF1R/SREBP1 experiments and does not establish adjuvant efficacy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-10
- Registry id: NCT06488378
- Phase: 1
- Setting: Metastatic or unresectable HER2-negative breast cancer with a deleterious or suspected deleterious germline/somatic BRCA1/2 mutation or germline PALB2 mutation, documented by a CLIA-certified laboratory
- Sponsor: Dana-Farber Cancer Institute
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT06488378: https://clinicaltrials.gov/study/NCT06488378

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Axatilimab](https://onco.cc/drugs/axatilimab/), [Olaparib](https://onco.cc/drugs/olaparib/)

---
JSON: https://onco.cc/api/v1/entities/nct06488378.json